{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(1)"],"submitter":["Lloyd MR"],"pubmed_abstract":["<h4>Purpose</h4>ESR1 mutations mediate resistance to antiestrogen therapy in hormone receptor-positive metastatic breast cancer (MBC). Elacestrant, an oral selective estrogen receptor degrader, improves progression-free survival over standard endocrine therapy in ESR1-mutant MBC. We assessed real-world elacestrant use and clinical-genomic factors associated with outcomes.<h4>Experimental design</h4>This study used the GuardantINFORM database, linking >42,000 real-world breast cancer cases with sequencing and claims data. We included patients with activating ESR1 mutations detected <6 months before elacestrant initiation (January 2023-March 2024). Outcomes of time-to-treatment-discontinuation, time-to-next-treatment (TTNT), and overall survival were estimated with Kaplan-Meier and Cox regre"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["169-178"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12770935"],"repository":["biostudies-literature"],"pubmed_title":["Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer."],"pmcid":["PMC12770935"],"pubmed_authors":["Lloyd MR","Weipert CM","Saha J","Wander SA","Ali A","Hamilton EP","Zhang N","Kalinsky K","Brufsky AM","Lipsyc-Sharf MD","Bardia A","Solomon SR"],"additional_accession":[]},"is_claimable":false,"name":"Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.","description":"<h4>Purpose</h4>ESR1 mutations mediate resistance to antiestrogen therapy in hormone receptor-positive metastatic breast cancer (MBC). Elacestrant, an oral selective estrogen receptor degrader, improves progression-free survival over standard endocrine therapy in ESR1-mutant MBC. We assessed real-world elacestrant use and clinical-genomic factors associated with outcomes.<h4>Experimental design</h4>This study used the GuardantINFORM database, linking >42,000 real-world breast cancer cases with sequencing and claims data. We included patients with activating ESR1 mutations detected <6 months before elacestrant initiation (January 2023-March 2024). Outcomes of time-to-treatment-discontinuation, time-to-next-treatment (TTNT), and overall survival were estimated with Kaplan-Meier and Cox regre","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-09T05:19:02.568Z","creation":"2026-06-09T03:07:24.572Z"},"accession":"S-EPMC12770935","cross_references":{"pubmed":["41201834"],"doi":["10.1158/1078-0432.CCR-25-3033"]}}